Endpoints News (@endpts) | teapawt

Endpoints News retweeted

Tom Randall@tsrandall1h

Biopharma is finally in a good mood. Our Biopharma Sentiment Index hit 105 in Q3, its first reading above neutral. A year ago it was 76. The lift came from rising assessments of current conditions for the industry. The future that insiders kept predicting has arrived 1/

1

4

1,131

Endpoints News retweeted

@ArmstrongDrew1h

Biotech vibes turned fully positive in Q3, for the first time since our @endpts survey has been running $XBI

1

4

1,450

Our Health Tech Day agenda is out, plus OpenAI’s Nate Gross joins us to talk about the company’s health ambitions. Early bird ends Friday. Reserve your spot: events.endpoints.news/health…

1

543

Antheia won a conditional $80M Defense Department loan to make generic drug ingredients in the US, as Trump pushes onshoring. endpoints.news/antheia-gets-…

Antheia gets $80M conditional DOD loan to onshore to the US

Antheia lands a conditional $80M loan from the Office of Strategic Capital to build US generic drug manufacturing.

1

740

Rapport’s oral drug licensed from J&J cleared a Phase 2 bipolar mania study, paving the way for registrational trials next year. endpoints.news/rapport-says-…

Rapport says drug it licensed from J&J clears Phase 2 bipolar mania study

Rapport’s RAP-219, licensed from J&J, hits Phase 2 bipolar mania goal, with registrational trials planned for 2H 2027.

3

1,006

ESMO first look: Zai Lab’s chemo-free combo posted an 80% response rate in small cell lung cancer, as GSK and Merck also detailed wins and setbacks. endpoints.news/esmo26-regula…

ESMO first look: Zai Lab, GSK, Merck and others detail wins, setbacks

ESMO 2026 abstracts: Zai Lab’s ZL-1310 posts 80% ORR in first-line SCLC, GSK’s ris-rez hits 61% and Merck details its RCC flop.

1

6

2,596

Exclusive: Sanofi tapped ScionxBio to screen its mRNA candidates, the startup’s first deal since splitting from Eleven Therapeutics. endpoints.news/sanofi-taps-n…

Exclusive: Sanofi taps new startup ScionxBio for long-acting RNA

ScionxBio signs first deal with Sanofi to screen mRNA candidates via its TERA platform. CEO Adi Gilboa-Geffen declined to share financial details.

1

3

1,445

Merck KGaA agreed to buy Silence Therapeutics for $1.3B, adding an siRNA drug headed into Phase 3 for a rare blood cancer. endpoints.news/merck-kgaa-wi…

Merck KGaA to buy Silence Therapeutics and its siRNA pipeline for $1.3B

Merck KGaA agrees to buy Silence Therapeutics for $1.3B, adding siRNA drug divesiran, which is headed to Phase 3 in polycythemia vera.

5

1,384

Veradermics’ oral twist on Rogaine won again in a late-stage trial, meeting all its goals in men with male pattern hair loss. endpoints.news/veradermics-o…

Veradermics' oral Rogaine wins again at growing hair in late-stage trial

Veradermics' VDPHL01, an extended-release oral minoxidil, hit all endpoints in a Phase 3 trial of 536 men with pattern hair loss, boosting the biotech's strong 2026.

2

7

2,694

After an FDA rejection, Disc Medicine’s drug for a rare disease that makes sun exposure painful hit all endpoints in Phase 3. endpoints.news/disc-medicine…

After FDA rejection, Disc Medicine's 'sun allergy' drug hits home run in Phase 3

Disc Medicine's bitopertin met all Phase 3 APOLLO endpoints for EPP, showing 12.2 more pain-free light hours and 41.4% PPIX reduction vs placebo.

4

17

2,856

Roche is going all in on China, paying Hansoh $400M upfront in an ADC alliance worth up to $15B. endpoints.news/roche-does-40…

Roche does $400M upfront, $15B deal with China's Hansoh

Roche pays $400M upfront in an ADC pact with Hansoh worth up to $15B, its sixth China deal since August.

10

2,082

Eli Lilly wants to study and improve the psychedelic ibogaine, its neuroscience chief said, following its $2.8B AtaiBeckley deal. endpoints.news/lilly-interes…

Lilly wants to study and improve the psychedelic ibogaine, its neuro leader says

Eli Lilly's neuroscience president Carole Ho expressed interest in ibogaine R&D at NYC's Psychedelic Healthcare Forum, following Lilly's $2.8B AtaiBeckley acquisition.

1

1

1,542

City Therapeutics, led by Alnylam alumni, priced a $200M IPO as it sets out to build an Alnylam 2.0 in RNAi. endpoints.news/city-therapeu…

City Therapeutics lands $200M IPO as it builds an Alnylam 2.0 in RNAi field

Alnylam alumni-led City Therapeutics prices $200M Nasdaq IPO at $18/share, advancing three liver-targeted RNAi programs.

2

1

1,610

Osivax’s lead flu vaccine flopped in a Phase 2b trial. The French biotech now plans to combine it with existing flu shots. endpoints.news/osivax-pivots…

Osivax pivots to combo approach after flu jab fails in Phase 2b

Osivax’s lead flu vaccine has flopped in a mid-stage trial. But the French biotech still holds out hope for the program, and plans to combine it with existing flu shots.

1

3

1,307

OrbiMed raised $3B across two new life sciences funds, including more than $1B for Asia. endpoints.news/orbimed-raise…

OrbiMed raises $3B in new life sciences funds, including $1B+ for Asia

OrbiMed raises $3B across two funds: $1.9B for US/Europe and $1B for Asia. Managing partner Carl Gordon cited AI and China's biopharma growth as key drivers.

1

2

1,220

Paul Stoffels isn’t giving up on Galapagos’ cell therapies. His new biotech, Armed Cell, has bought the preclinical CAR-T work. endpoints.news/paul-stoffels…

Paul Stoffels seeks to revive Galapagos’ cell therapies at new biotech Armed Cell

Paul Stoffels’ new Armed Cell Therapeutics buys Lakefront’s (ex-Galapagos) preclinical CAR-T work for $9M upfront, $230M in biobucks.

3

1,256

OMass raised $310M, one of the largest private financings for a UK biotech in recent years, to tackle a genetic adrenal disorder. endpoints.news/omass-therape…

OMass Therapeutics collects $310M to chase Neurocrine, Vertex in genetic adrenal disorder

OMass has raised one of the largest private financings for a UK biotech in recent years as it seeks to follow in the footsteps of Neurocrine and Vertex-acquired Crinetics in congenital adrenal...

1

8

1,911

Gilead is paying Vir $65M upfront in a deal for three T cell engagers aimed at solid tumors. endpoints.news/vir-makes-sol…

Vir makes solid tumor T cell engager deal with Gilead

Gilead pays Vir Biotechnology $65M upfront plus $25M investment for 3 T cell engager solid tumor therapies. Deal includes $1.79B in potential milestones. Vir shares up 78% YTD.

1

4

1,542

Verastem had a busy morning: new KRAS data in pancreatic cancer, a $250M raise and its CEO’s departure. endpoints.news/verastem-make…

Verastem makes its stand as a RevMed competitor in pancreatic cancer

Verastem Oncology announced VS-7375 data showing 41% response rate in pancreatic cancer, raised $250M, and CEO Dan Paterson stepping down, replaced by Michael Bailey.

2

1,288

Zealand inked a deal worth up to $1.3B to design obesity drugs with Generate Biomedicines’ AI platform. endpoints.news/zealand-inks-…

Zealand inks up to $1.3B deal for AI-designed obesity treatments

Zealand Pharma pays $30M upfront in a deal worth up to $1.3B to design obesity proteins with Generate’s AI platform.

2

1,312